Large interindividual variations exist in human performance at high altitude. Some of these diVerences may be associated with certain genetic variants/genotype combinations (Gomez-Gallego et al. 2009 ). Studying microvascular, cellular and metabolic mechanisms of adaptation to high altitude helps to better understand individual physiological responses to hypoxia in high-performance athletes as well as in patients suVering from critical illness. Investigations such as the study presented by Sanchis-Gomar add valuable information on the underlying aspects of human physiology. There is an obvious eVect on oxygen transport capacity, comparable in magnitude and quality to external supply with erythropoietin. The general question, of course, remains whether doping measures-even if as 'natural' as intermittent reduction of available oxygen-should be seen as a model for therapeutic approaches.
Damage caused by reactive oxygen species (ROS) is one of the potential problems when hypoxic stress occurs. Injury from prolonged hypobaric hypoxia, which is a characteristic of high altitude, is known to induce oxidative injury by increasing the generation of ROS and decreasing the eVectiveness of the antioxidant defense system. However, much attention has been directed towards a 'live-high train-low' (LHTL) training approach: athletes live and sleep at high altitude, but regularly descend for training sessions to lower altitude (Levine and Stray-Gundersen 1997) .
A recent meta-analysis strikingly showed problems of heterogeneity between previous studies and calls for enhancement of protocols used, such as double-blind designs, to exclude biasing placebo, nocebo, or training-camp eVects (Bonetti and Hopkins 2009) .
Most hemodynamic variables, such as heart rate, cardiac output, peripheral resistance and systemic arterial pressure, increase due to chemoreceptor-mediated sympathetic activation during acute episodes of hypoxia in humans. However, experimental evidence has suggested intermittent hypoxia conditioning to be safe for prevention and treatment of hypertension (Serebrovskaya et al. 2008) . The question remains under exactly which circumstances advantages of intermittent hypoxia treatment may outweigh possible long-term risks. This dilemma has been addressed at least in part by several studies, but a general consensus is still lacking. More well-controlled human investigations that focus on long-term perspectives within this framework are clearly needed. As far as only performance increase in athletes is targeted, ethical caveats linger, and should be seen as an important part of the equation.
